Seres Therapeutics is a biotechnology company focused on developing innovative therapies based on the human microbiome. Their primary goal is to harness the power of beneficial bacteria to treat various diseases, particularly gastrointestinal disorders. The company is known for its lead product, SER-109, which is designed to prevent recurrent Clostridium difficile infections. By restoring a healthy balance of gut bacteria, Seres aims to improve patient outcomes and provide new treatment options for those suffering from microbiome-related conditions.